Cargando…
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance
BACKGROUND: New treatments are currently offering new opportunities and challenges in clinical management and research in the migraine field. There is the need of homogenous criteria to identify candidates for treatment escalation as well as of reliable criteria to identify refractoriness to treatme...
Autores principales: | Sacco, Simona, Lampl, Christian, Maassen van den Brink, Antoinette, Caponnetto, Valeria, Braschinsky, Mark, Ducros, Anne, Little, Patrick, Pozo-Rosich, Patricia, Reuter, Uwe, Ruiz de la Torre, Elena, Sanchez Del Rio, Margarita, Sinclair, Alexandra J., Martelletti, Paolo, Katsarava, Zaza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130435/ https://www.ncbi.nlm.nih.gov/pubmed/34006218 http://dx.doi.org/10.1186/s10194-021-01252-4 |
Ejemplares similares
-
European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)
por: Sacco, Simona, et al.
Publicado: (2020) -
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure
por: Sacco, Simona, et al.
Publicado: (2022) -
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
por: Sacco, Simona, et al.
Publicado: (2022) -
Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
por: Bendtsen, Lars, et al.
Publicado: (2018) -
Refractory chronic migraine: a Consensus Statement on clinical definition from the European Headache Federation
por: Martelletti, Paolo, et al.
Publicado: (2014)